Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

Held every four years, the Global Refugee Forum is the world’s largest international gathering on refugees. It brings together UN Member States, non-governmental organizations, the private sector, ...

Healthcare Global Enterprises Ltd., incorporated in the year 1998, is a Small Cap company (having a market cap of Rs 7,074.69 Crore) operating in Hospitals & Allied Services sector. Healthcare Global ...